FLT3 and acute myeloid leukemia: In a single-arm study, post-transplantation midostaurin use also was associated with a significantly improved OS (multivariable P=.01 versus no midostaurin) and event-free survival (multi-variable P=.004 versus no midostaurin) versus historical controls with FLT3-ITD–positive AML in first CR/CRi [22].